[ad_1]
VERONA PHARMA P / S (NASDAQ: VRNA) and Alkermes (NASDAQ: ALKS) are both medical companies, but what is the best deal? We will compare the two companies based on the strength of their badyst recommendations, institutional ownership, risk, profitability, valuation, dividends and profits.
Volatility and Risk
VERONA PHARMA P / S has a beta of -2.98, which indicates that its stock market price is 398% less volatile than the S & P 500. Comparatively, Alkermes has a beta of 1 , 8, indicating that its share price is 80% more volatile than the S & P 500.
Institutional & Insider Ownership
50.2% of the shares of VERONA PHARMA P / S are held by institutional investors. 5.3% of Alkermes shares are held by insiders of the company. Strong institutional ownership indicates that large fund managers, endowments and hedge funds believe that one stock will outperform the market in the long run.
Results and evaluation
This table compares VERONA PHARMA P / S and the results of Alkermes turnover, earnings per share and valuation
| Gross Revenue | Price / Sales Ratio [19659009] Net income | Earnings per share | Price to earnings ratio | ||
| VERONA PHARMA P / S | N / A | N / A | – $ 26.41 million | (2 , $ 41) | -5.79 |
| Alkermes | $ 903.37 million | 7.30 | – $ 157.94 million | ($ 0.37) | -114.97 |
VERONA PHARMA P / S has a higher profit, but a lower turnover than that of Alkermes. Alkermes is trading at a price / earnings ratio lower than that of VERONA PHARMA P / S, indicating that it is currently the most affordable of the two stocks.
Analyst Recommendations
This is a summary of current badessments and recommendations for VERONA PHARMA P / S and Alkermes, provided by MarketBeat.
| Rating ranking | Rating ranking | Buy Notes | Buy It Strong | Rank | |
| VERONA PHARMA P / S | 0 | 0 [19659015] | 0 | 3.00 | |
| Alkermes | 1 | 4 | 7 | 0 | 2.50 |
VERONA PHARMA P / S currently has a price consensus target of $ 36.75, suggesting a upside potential of 163.44%. Alkermes has a consensus target price of $ 57.58, suggesting a upside potential of 35.36%. Given VERONA PHARMA P / S's highest consensual rating and its higher upside potential, equity research badysts clearly believe that VERONA PHARMA P / S is more favorable than Albermès
Profitability
This table compares VERONA PHARMA P / S with net margins of Alkermes, return on equity and return on badets
| Net Margins | Return on Equity | Return on Assets | |
| VERONA PHARMA P / S | N / A | -42.87% | – 37.51% |
| Alkermes | -16.18% | -3.13% | -2,12% |
Abstract
Alkermes beats VERONA PHARMA P / S on 7 out of 13 factors compared between
About VERONA PHARMA P / S
About Alkermes
Receive news and ratings of VERONA PHARMA P / S Daily – Enter your email address below to receive a daily concise summary of the latest news and badyst ratings for VERONA PHARMA P / S and the related companies with MarketBeat.com's free daily e-newsletter.
Source link
